Tony Hoos to replace Anders Ullman as Head of R&D and Medical Affairs and Chief Medical Officer from 1 April 2023.
Anton (Tony) Hoos, M.D., Ph.D., MBA will become Head of R&D and Medical Affairs and Chief Medical Officer and replace Anders Ullman, M.D., Ph.D. who will retire.
Dr Hoos brings more than three decades of experience from the global pharmaceutical industry, including positions at Amgen, GSK and Aventis and most recently as a member of the board of Patient Focused Medicine Development, a non-profit organisation dedicated to bringing the voice of patients into the development of medicines. Similar to Anders Ullman, Tony Hoos will be based in Basel, Switzerland, report to CEO Guido Oelkers and become a member of the Sobi Executive Committee.
“Tony brings with him a wealth of global experience to lead our R&D and medical activities. As an expert in patient engagement, Tony will bring new and important insights. Tony will take over a well-run organisation from Anders, who has over the past year successfully transformed the ways the function is working. I would like to thank Anders for his long-term commitment to Sobi first as a board member and then in the current job,” says Guido Oelkers, CEO, Sobi.